CL2009001152A1 - Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. - Google Patents

Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.

Info

Publication number
CL2009001152A1
CL2009001152A1 CL2009001152A CL2009001152A CL2009001152A1 CL 2009001152 A1 CL2009001152 A1 CL 2009001152A1 CL 2009001152 A CL2009001152 A CL 2009001152A CL 2009001152 A CL2009001152 A CL 2009001152A CL 2009001152 A1 CL2009001152 A1 CL 2009001152A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical composition
pyrrolo
pyridin
amide
Prior art date
Application number
CL2009001152A
Other languages
English (en)
Inventor
Eli M Wallace
Bin Wang
Huerou Yvan Le
James P Blake
Indrani W Gunwardana
Pete Mohr
Mark Chicarelli
Michael Lyon
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001152(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CL2009001152A1 publication Critical patent/CL2009001152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

LA PRESENTE INVENCIÓN TRATA SOBRE COMPUESTOS DE FÓRMULA I COMO INHIBIDORES DE CHK1, Y UN PROCESO PARA PREPARAR DICHOS COMPUESTOS. TAMBIÉN SE REVELA UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE DICHO COMPUESTO Y SU USO EN EL TRATAMIENTO UNA ENFERMEDAD HIPERPROLIFERATIVA.
CL2009001152A 2008-05-13 2009-05-12 Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. CL2009001152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13

Publications (1)

Publication Number Publication Date
CL2009001152A1 true CL2009001152A1 (es) 2009-10-16

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001152A CL2009001152A1 (es) 2008-05-13 2009-05-12 Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.

Country Status (30)

Country Link
US (6) US8178131B2 (es)
EP (2) EP2307409B1 (es)
JP (2) JP5703212B2 (es)
KR (2) KR101643426B1 (es)
CN (3) CN104926810B (es)
AR (1) AR071717A1 (es)
AU (1) AU2009246402B2 (es)
BR (1) BRPI0913580B8 (es)
CA (1) CA2724262C (es)
CL (1) CL2009001152A1 (es)
CO (1) CO6321244A2 (es)
CR (1) CR11803A (es)
CY (1) CY1116692T1 (es)
DK (1) DK2307409T3 (es)
ES (1) ES2552643T3 (es)
HK (2) HK1152035A1 (es)
HR (1) HRP20151018T1 (es)
HU (1) HUE026160T2 (es)
IL (1) IL209258A (es)
MX (1) MX2010012449A (es)
NZ (1) NZ589318A (es)
PH (1) PH12013501779A1 (es)
PL (1) PL2307409T3 (es)
PT (1) PT2307409E (es)
RS (1) RS54358B1 (es)
RU (1) RU2517194C2 (es)
SI (1) SI2307409T1 (es)
TW (2) TWI458727B (es)
UA (1) UA111933C2 (es)
WO (1) WO2009140320A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CA2711741A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
NZ596125A (en) * 2009-04-11 2012-08-31 Array Biopharma Inc Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
CA2808543C (en) 2010-08-20 2016-01-26 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
AU2012254082B2 (en) 2011-02-25 2016-12-08 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
EP2702063A1 (en) 2011-04-29 2014-03-05 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
WO2013163109A1 (en) 2012-04-23 2013-10-31 Genentech, Inc. Intermediates and processes for preparing compounds
EP3024457A4 (en) 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
US10329288B2 (en) 2013-08-22 2019-06-25 Genentech, Inc. Process for preparing a compound
ES2785053T3 (es) * 2013-09-25 2020-10-05 Vertex Pharma Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US9580416B2 (en) 2014-07-02 2017-02-28 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MA41599A (fr) 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CN107708414B (zh) 2015-06-30 2022-02-25 首尔伟傲世有限公司 适用紫外线发光二极管的捕虫器
EP4014977A1 (en) * 2015-11-04 2022-06-22 Merck Patent GmbH Pyrimidine compounds with btk inhibitory activity for use in treating cancer
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
CA3024180A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3817820A1 (en) 2018-07-03 2021-05-12 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
BR112023023463A2 (pt) 2021-05-14 2024-01-30 Syndax Pharmaceuticals Inc Inibidores da interação menin-mll

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE217309T1 (de) * 1993-10-14 2002-05-15 Abbott Lab Verbindungen des chinolizinon-typs
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
MXPA02010222A (es) 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
CN101014597A (zh) * 2004-04-02 2007-08-08 沃泰克斯药物股份有限公司 可用作rock和其他蛋白激酶抑制剂的吖吲哚
WO2005112938A2 (en) * 2004-04-13 2005-12-01 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
RU2435769C2 (ru) * 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
KR101149954B1 (ko) * 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
PE20070543A1 (es) 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
ES2700433T3 (es) 2005-12-13 2019-02-15 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
ES2878130T3 (es) 2006-04-25 2021-11-18 Astex Therapeutics Ltd Derivados de purina y deazapurina como compuestos farmacéuticos
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
WO2009004329A1 (en) 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US8603998B2 (en) 2007-11-07 2013-12-10 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CN101959887B (zh) * 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CA2711741A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1

Also Published As

Publication number Publication date
KR20140093266A (ko) 2014-07-25
CN102089307A (zh) 2011-06-08
MX2010012449A (es) 2011-05-25
SI2307409T1 (sl) 2015-11-30
KR101657856B1 (ko) 2016-09-19
CA2724262C (en) 2017-08-15
PH12013501779B1 (en) 2014-08-27
EP2990407B1 (en) 2019-10-16
JP5703212B2 (ja) 2015-04-15
US8758830B2 (en) 2014-06-24
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
BRPI0913580B1 (pt) 2020-03-10
CN104926810A (zh) 2015-09-23
IL209258A0 (en) 2011-01-31
EP2990407A1 (en) 2016-03-02
HRP20151018T1 (hr) 2015-10-23
RS54358B1 (en) 2016-04-28
HUE026160T2 (en) 2016-05-30
HK1152035A1 (en) 2012-02-17
CA2724262A1 (en) 2009-11-19
US9969727B2 (en) 2018-05-15
IL209258A (en) 2017-01-31
HK1219950A1 (zh) 2017-04-21
BRPI0913580B8 (pt) 2021-05-25
BRPI0913580A2 (pt) 2015-10-20
RU2010150786A (ru) 2012-06-20
US20130045286A1 (en) 2013-02-21
KR20110008102A (ko) 2011-01-25
PT2307409E (pt) 2015-11-04
CN109942575A (zh) 2019-06-28
WO2009140320A1 (en) 2009-11-19
KR101643426B1 (ko) 2016-07-27
RU2517194C2 (ru) 2014-05-27
TWI554512B (zh) 2016-10-21
EP2307409B1 (en) 2015-08-12
CR11803A (es) 2011-02-11
CN104926810B (zh) 2019-02-19
AU2009246402A1 (en) 2009-11-19
TW201529573A (zh) 2015-08-01
PH12013501779A1 (en) 2014-08-27
PL2307409T3 (pl) 2016-01-29
JP2015098482A (ja) 2015-05-28
ES2552643T3 (es) 2015-12-01
NZ589318A (en) 2011-06-30
US20140100369A1 (en) 2014-04-10
JP2011520896A (ja) 2011-07-21
US9365568B2 (en) 2016-06-14
US20160368916A1 (en) 2016-12-22
TWI458727B (zh) 2014-11-01
US20110070317A1 (en) 2011-03-24
TW201002707A (en) 2010-01-16
AR071717A1 (es) 2010-07-07
CO6321244A2 (es) 2011-09-20
CY1116692T1 (el) 2017-03-15
US20150322061A1 (en) 2015-11-12
CN102089307B (zh) 2015-07-01
AU2009246402B2 (en) 2013-05-23
US8981085B2 (en) 2015-03-17
UA111933C2 (uk) 2016-07-11
US20140243520A1 (en) 2014-08-28
US8545897B2 (en) 2013-10-01
US8178131B2 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
CL2009001152A1 (es) Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
HK1149258A1 (en) Compounds
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX344669B (es) Agente antiplaquetas novedoso.
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
NZ630457A (en) Compounds useful as inhibitors of atr kinase
ECSP11011526A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
UA106057C2 (uk) Спосіб одержання сполук дигідроінденаміду, фармацевтична композиція, що містить дані сполуки, та їх застосування як інгібітора протеїнкінази
EA200970156A1 (ru) Пиридизиноновые производные
UY33075A (es) Derivados de ciclohexano y usos de los mismos
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
TW200942529A (en) Pyrrolidinyl derivatives and uses thereof
NZ591837A (en) Amino acid derivative
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение